These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 20368393)
1. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Sugaya N; Ohashi Y Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393 [TBL] [Abstract][Full Text] [Related]
2. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu H; Kawai N Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296 [TBL] [Abstract][Full Text] [Related]
3. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y; Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975 [TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. Watanabe A J Infect Chemother; 2013 Feb; 19(1):89-97. PubMed ID: 22907567 [TBL] [Abstract][Full Text] [Related]
5. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Wang K; Shun-Shin M; Gill P; Perera R; Harnden A Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD002744. PubMed ID: 22513907 [TBL] [Abstract][Full Text] [Related]
6. Neuraminidase inhibitors for preventing and treating influenza in children. Wang K; Shun-Shin M; Gill P; Perera R; Harnden A Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949 [TBL] [Abstract][Full Text] [Related]
7. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080 [TBL] [Abstract][Full Text] [Related]
9. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015 [TBL] [Abstract][Full Text] [Related]
10. The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season. Ikematsu H; Kawai N; Iwaki N; Kashiwagi S J Infect Chemother; 2014 Feb; 20(2):81-5. PubMed ID: 24486167 [TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. Higashiguchi M; Matsumoto T; Fujii T Antivir Ther; 2018; 23(2):157-165. PubMed ID: 28869418 [TBL] [Abstract][Full Text] [Related]
12. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons. Sun Y; Wagatsuma K; Saito R; Sato I; Kawashima T; Saito T; Shimada Y; Ono Y; Kakuya F; Minato M; Kodo N; Suzuki E; Kitano A; Chon I; Phyu WW; Li J; Watanabe H Antiviral Res; 2024 Aug; 228():105938. PubMed ID: 38897317 [TBL] [Abstract][Full Text] [Related]
13. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015. Ikematsu H; Kawai N; Iwaki N; Kashiwagi S J Infect Chemother; 2016 Sep; 22(9):605-10. PubMed ID: 27493024 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model. Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190 [TBL] [Abstract][Full Text] [Related]
15. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Kubo S; Tomozawa T; Kakuta M; Tokumitsu A; Yamashita M Antimicrob Agents Chemother; 2010 Mar; 54(3):1256-64. PubMed ID: 20047917 [TBL] [Abstract][Full Text] [Related]
16. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870 [TBL] [Abstract][Full Text] [Related]
17. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. Vavricka CJ; Li Q; Wu Y; Qi J; Wang M; Liu Y; Gao F; Liu J; Feng E; He J; Wang J; Liu H; Jiang H; Gao GF PLoS Pathog; 2011 Oct; 7(10):e1002249. PubMed ID: 22028647 [TBL] [Abstract][Full Text] [Related]
18. In vitro neuraminidase inhibitory concentration (IC Ikematsu H; Kawai N; Tani N; Chong Y; Bando T; Iwaki N; Kashiwagi S J Infect Chemother; 2020 Aug; 26(8):775-779. PubMed ID: 32249161 [TBL] [Abstract][Full Text] [Related]
19. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Yamashita M Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016 [TBL] [Abstract][Full Text] [Related]
20. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons. Ikematsu H; Kawai N; Iwaki N; Kashiwagi S J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]